Long-term safety and efficacy of long-acting pasireotide in acromegaly

ConclusionsThe results support the long-term efficacy and safety of pasireotide LAR for acromegaly and support the potential delayed effect of treatment on IGF-1 normalization.

http://rd.springer.com/10.1007/s12020-021-02782-2

Source: Endocrine - October 13, 2021 Category: Endocrinology Source Type: research